Stock GBLX GB SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials GB Sciences, Inc.

Equities

GBLX

US3615441090

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 20:41:44 17/05/2024 BST 		5-day change 1st Jan Change
0.0095 USD +11.76% Intraday chart for GB Sciences, Inc. +41.79% +48.44%
02-12 GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
2023 GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 76.53 41.97 9.11 17.79 8.92 6.826
Enterprise Value (EV) 1 80.51 50.57 18.96 20.97 10.07 8.112
P/E ratio -2.75 x -1.48 x -0.7 x -4.75 x -16.8 x -1.56 x
Yield - - - - - -
Capitalization / Revenue 30.5 x 12.1 x 2.92 x - - -
EV / Revenue 32.1 x 14.6 x 6.08 x - - -
EV / EBITDA -4.73 x -3.38 x -2.65 x -10.7 x -5.6 x -5.04 x
EV / FCF -7.07 x -3.43 x -2.56 x 6.52 x -20.5 x -11 x
FCF Yield -14.1% -29.1% -39% 15.3% -4.88% -9.11%
Price to Book 6.3 x 5.42 x -104 x -13.3 x -5.12 x -1.56 x
Nbr of stocks (in thousands) 160,785 224,674 272,767 286,989 317,436 379,206
Reference price 2 0.4760 0.1868 0.0334 0.0620 0.0281 0.0180
Announcement Date 29/06/18 15/07/19 28/08/20 06/07/21 30/06/22 14/07/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 2.51 3.455 3.121 - - -
EBITDA 1 -17.02 -14.97 -7.154 -1.954 -1.798 -1.611
EBIT 1 -17.82 -15.59 -7.365 -2.002 -1.869 -1.672
Operating Margin -710.04% -451.41% -236.01% - - -
Earnings before Tax (EBT) 1 -23.16 -24.15 -11.55 -3.333 -0.1465 -4.125
Net income 1 -22.97 -23.65 -12.37 -3.725 -0.5309 -4.125
Net margin -915.17% -684.7% -396.51% - - -
EPS 2 -0.1728 -0.1265 -0.0479 -0.0131 -0.001671 -0.0115
Free Cash Flow 1 -11.38 -14.73 -7.397 3.218 -0.4911 -0.7394
FCF margin -453.41% -426.5% -237.04% - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 29/06/18 15/07/19 28/08/20 06/07/21 30/06/22 14/07/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: März 2018 2019 2020 2021 2022 2023
Net Debt 1 3.97 8.6 9.85 3.18 1.15 1.29
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -0.2335 x -0.5744 x -1.377 x -1.627 x -0.6401 x -0.7986 x
Free Cash Flow 1 -11.4 -14.7 -7.4 3.22 -0.49 -0.74
ROE (net income / shareholders' equity) -193% -151% -136% 427% 9% 133%
ROA (Net income/ Total Assets) -60.1% -36% -20.7% -9.94% -17.5% -72%
Assets 1 38.21 65.61 59.64 37.46 3.035 5.727
Book Value Per Share 2 0.0800 0.0300 -0 -0 -0.0100 -0.0100
Cash Flow per Share 2 0.0200 0 0 0 0 0
Capex 1 3.43 10.6 0.2 - - -
Capex / Sales 136.62% 306.36% 6.48% - - -
Announcement Date 29/06/18 15/07/19 28/08/20 06/07/21 30/06/22 14/07/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GB SCIENCES, INC. Stock GB Sciences, Inc.
+48.44% 3.86M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.09% 42.12B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.05B
CELLTRION, INC. Stock Celltrion, Inc.
-4.96% 29.18B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.18% 26.02B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.95% 18.9B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.61% 13.21B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.73% 12.17B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.31% 12.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-6.26% 11.42B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GBLX Stock
  4. Financials GB Sciences, Inc.